First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis

被引：0
|
作者：
Weiting Liao
Jiaxing Huang
Qiuji Wu
Feng Wen
Nan Zhang
Kexun Zhou
Liangliang Bai
Qiu Li
机构：
[1] Sichuan University,Department of Medical Oncology, Cancer Center, West China Hospital
[2] Sichuan University,West China Biomedical Big Data Center
来源：
Breast Cancer | 2020年 / 27卷
关键词：
Cost-effectiveness analysis; Breast cancer; Hormone-receptor-positive; Fulvestrant; Anastrozole; Dual endocrine therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：399 / 404
页数：5
相关论文
共 50 条
  • [31] Adding capivasertib to fulvestrant in patients with hormone receptor-positive advanced breast cancer: a cost-effectiveness analysis
    Lang, Yitian
    Chai, Qingqing
    Lin, Yan
    Wu, Bin
    Liu, Xiaoyan
    FRONTIERS IN PHARMACOLOGY, 2025, 15
  • [32] A cost-effectiveness analysis of palbociclib plus letrozole as first-line treatment for estrogen receptor-positive, HER2-negative, metastatic breast cancer.
    Matter-Walstra, Klazien
    Schwenkglenks, Matthias
    Brauchli, Peter
    Klingbiel, Dirk
    Dedes, Konstantin J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [33] Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naïve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK
    Claire Telford
    Evelina Bertranou
    Samuel Large
    Hilary Phelps
    Mattias Ekman
    Christopher Livings
    PharmacoEconomics - Open, 2019, 3 : 559 - 570
  • [34] Goserelin plus anastrozole for the treatment of premenopausal women with hormone receptor positive, recurrent/metastatic breast cancer
    Carlson, RW
    Schurmann, CM
    Rivera, E
    Chung, CT
    Phan, SC
    Dice, EK
    Arun, B
    Thomas, E
    Valero, V
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S237 - S238
  • [35] Cost-Effectiveness of Atezolizumab Plus Chemotherapy as First-Line Therapy for Metastatic Urothelial Cancer
    Qin, Shuxia
    Yi, Lidan
    Li, Sini
    Tan, Chongqing
    Zeng, Xiaohui
    Wang, Liting
    Peng, Ye
    Wan, Xiaomin
    ADVANCES IN THERAPY, 2021, 38 (06) : 3399 - 3408
  • [36] Cost-Effectiveness of Atezolizumab Plus Chemotherapy as First-Line Therapy for Metastatic Urothelial Cancer
    Shuxia Qin
    Lidan Yi
    Sini Li
    Chongqing Tan
    Xiaohui Zeng
    Liting Wang
    Ye Peng
    Xiaomin Wan
    Advances in Therapy, 2021, 38 : 3399 - 3408
  • [37] COST-EFFECTIVENESS ANALYSIS OF FULVESTRANT IN THE TREATMENT OF METASTATIC BREAST CANCER IN SECOND-LINE CHEMOTHERAPY
    Krysanov, I
    Krysanova, V
    VALUE IN HEALTH, 2014, 17 (07) : A637 - A637
  • [38] Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer
    Vakaramoko Diaby
    Georges Adunlin
    Simon B. Zeichner
    Kiran Avancha
    Gilberto Lopes
    Stefan Gluck
    Alberto J. Montero
    Breast Cancer Research and Treatment, 2014, 147 : 433 - 441
  • [39] Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
    Baselga, Jose
    Campone, Mario
    Piccart, Martine
    Burris, Howard A., III
    Rugo, Hope S.
    Sahmoud, Tarek
    Noguchi, Shinzaburo
    Gnant, Michael
    Pritchard, Kathleen I.
    Lebrun, Fabienne
    Beck, J. Thaddeus
    Ito, Yoshinori
    Yardley, Denise
    Deleu, Ines
    Perez, Alejandra
    Bachelot, Thomas
    Vittori, Luc
    Xu, Zhiying
    Mukhopadhyay, Pabak
    Lebwohl, David
    Hortobagyi, Gabriel N.
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (06): : 520 - 529
  • [40] Fulvestrant: A guide to its use in hormone receptor-positive metastatic breast cancer in postmenopausal women in the EU
    Scott L.J.
    Croxtall J.D.
    McKeage K.
    Drugs & Therapy Perspectives, 2014, 30 (2) : 42 - 47
12345